Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04174196 | A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | active not recruiting | Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | active not recruiting | Phase 1 / Phase 2 | 32 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 |
| clinicaltrials |
| NCT07162012 | Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma(Anti-EBV TCR-T) | recruiting | Early Phase 1 | 24 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07257510 | Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma | recruiting | N/A | 34 | Peking University Third HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259122 | A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia(ZBR in WM) | not yet recruiting | Phase 2 | 43 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT00898235 | Collection of Samples and Clinical Data From Patients With Amyloid Diseases | recruiting | — | 10,000 | Boston Medical CenterOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05312255 | Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma | recruiting | N/A | 175 | Roswell Park Cancer InstituteOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07248176 | Universal CAR-T Cell Therapy for MM | recruiting | N/A | 6 | Bioray LaboratoriesINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT04091126 | Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma(DREAMM 9) | active not recruiting | Phase 1 | 118 | GlaxoSmithKlineINDUSTRY | 10 | Nov 28, 2025 | clinicaltrials |
| NCT07188090 | Mozobil for Autologous Hematopoietic Stem Cell Transplantation(HSCT) | recruiting | Phase 2 | 100 | Thomas Jefferson UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07253103 | Effects of a Resistance Physical Exercise Program in Multiple Myeloma Patients | not yet recruiting | N/A | 50 | University of SalamancaOTHER | 0 | Nov 28, 2025 | clinicaltrials |
| NCT07254754 | Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma(LATE-R-GEL-23) | recruiting | Phase 2 | 45 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT02570542 | Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04484012 | Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 36 | City of Hope Medical CenterOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06508775 | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies(LONGSAFE) | recruiting | N/A | 40 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06547866 | Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia(WAZABI) | not yet recruiting | Phase 2 | 102 | French Innovative Leukemia OrganisationOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07003555 | Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07003568 | Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07084662 | Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma | recruiting | Phase 2 / Phase 3 | 80 | Sun Yat-sen UniversityOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05741359 | The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma | recruiting | Phase 1 | 18 | Bioray LaboratoriesINDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06958705 | Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy | recruiting | Phase 2 | 79 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07139509 | Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma(UCAR-T_MM-XA) | recruiting | Phase 1 | 18 | Xi'an No.3 HospitalOTHER_GOV | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07247383 | Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma | active not recruiting | Phase 2 | 39 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07248163 | Universal CAR-T Cell Therapy for NHL | recruiting | N/A | 6 | Bioray LaboratoriesINDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07249073 | CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma | recruiting | Early Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06581848 | Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). | active not recruiting | — | 150 | PfizerINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07173790 | Watch and Wait or Worry and Wait in Indolent Lymphoma | enrolling by invitation | — | 250 | Seoul National University HospitalOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07236021 | e-Motion : Promoting Emotion Regulation in Chronic Cancer | recruiting | N/A | 30 | Université Libre de BruxellesOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03717844 | Registry for Adults With Plasma Cell Disorders (PCD's) | recruiting | — | 2,000 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04795882 | A New Study Evaluating the Activity of Modular CAR T for mYeloma(MCARTY) | recruiting | Phase 1 | 27 | University College, LondonOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06707259 | Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL | recruiting | Phase 1 | 24 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07239323 | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies | recruiting | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06449885 | A Cohort Study in Newly Diagnosed MZL | recruiting | — | 2,500 | Fudan UniversityOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT03436602 | Personalized Risk Stratification Model of Follicular Lymphoma Patients | active not recruiting | — | 370 | Oncology Institute of Southern SwitzerlandOTHER | 2 | Nov 18, 2025 | clinicaltrials |
| NCT07180992 | Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma(MONOMM) | recruiting | — | 25 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07188077 | Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma | recruiting | — | 20 | Ting YANGOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07233720 | Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma | recruiting | — | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07053670 | A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )(CT1190B) | recruiting | Phase 1 | 27 | Tongji HospitalOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT02641145 | Molecular Imaging of Primary Amyloid Cardiomyopathy(MICA) | recruiting | N/A | 171 | Brigham and Women's HospitalOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 120 | CRISPR Therapeutics AGINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT06550141 | Emapalumab Prevention of CAR-T Cell Associated Toxicities | recruiting | Phase 2 | 28 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06055894 | A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS) | recruiting | N/A | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT02253316 | Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma | active not recruiting | Phase 2 | 236 | Washington University School of MedicineOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02337985 | Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03375619 | Long-term Follow-up Study of Patients Receiving CAR-T Cells | recruiting | — | 500 | Medical College of WisconsinOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04114084 | Sleep Apnea in Patients With MGUS and MM | recruiting | — | 200 | Michael TomassonOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04148430 | A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy | active not recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT02633111 | DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas | active not recruiting | — | 501 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 2, 2025source: clinicaltrials